Bristol-Myers Squibb reported positive Phase 3 trial results for Sotyktu in treating psoriatic arthritis, boosting investor confidence with an 8% stock price increase. The European Commission approved subcutaneous use of Opdivo, and the company collaborated with BioNTech for cancer treatment. These developments, alongside promising data on targeted protein degradation research, suggest strong growth potential amid generic competition for legacy drugs.